• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

11
5
4
4
4

COUNTRY

4
1
1
1

CATEGORIES

  • 14
  • 12
  • 10
  • 7
  • 6
  • 3
  • 2
  • 2
  • 1

PRICE

20
30
45
55

PUBLISHED

1
3
5
55

PRODUCT TYPE

41
14

Search "Eurand-Company Report" returned 55 results.

PRODUCT TITLE
Eurand Acquisition Manual Eurand Acquisition Manual - Product Thumbnail Image

Eurand Acquisition Manual

The Acquisition Manual on Eurand is published for two purposes, firstly to identify the company as a potential acquisition target and secondly, to fully analyse all aspects of Eurand so that potential...

February 2015

Eurand N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain...

December 2014
FROM
Cystic Fibrosis - Global Strategic Business Report Cystic Fibrosis - Global Strategic Business Report - Product Thumbnail Image

Cystic Fibrosis - Global Strategic Business Report

This report analyzes the US market for Cystic Fibrosis in Millions of US$ Annual estimates and forecasts are provided for the period of 2007 through 2015 Also, a six-year historic analysis is provided...

June 2010
FROM

Pediatric Drug Delivery: Technology and Product Opportunities, 2nd Edition

This 250+ page report provides a comprehensive overview of the pediatric drug delivery market and includes relevant market data, key players, pharmaceutical product information, drug delivery technology...

October 2010
FROM
Pancreatic Diseases - Pipeline Review, H2 2012 Pancreatic Diseases - Pipeline Review, H2 2012 - Product Thumbnail Image

Pancreatic Diseases - Pipeline Review, H2 2012

Pancreatic Diseases – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Pancreatic Diseases - Pipeline Review, H2 2012', provides an overview of the Pancreatic Diseases therapeutic pipeline....

August 2012
FROM

Guide to U.S. Specialty Pharmaceutical Market: Companies, Products and Market Data

The growing U S specialty pharmaceuticals market is comprised of more than 90 companies marketing more than 550 prescription pharmaceutical products Our report covers more than 10 therapeutic categories...

January 2011
FROM
Aptalis Pharma Inc. - Product Pipeline Review - 2012 Aptalis Pharma Inc. - Product Pipeline Review - 2012 - Product Thumbnail Image

Aptalis Pharma Inc. - Product Pipeline Review - 2012

Aptalis Pharma Inc. – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “Aptalis Pharma Inc. - Product Pipeline Review - 2012” provides data on the Aptalis Pharma...

September 2012
FROM

Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential

“Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” provides key data, information and analysis of the major trends and issues in Nanotechnology...

December 2010
FROM
Summary: Aptalis Pharma Inc. May 13 Summary: Aptalis Pharma Inc. May 13 - Product Thumbnail Image

Summary: Aptalis Pharma Inc. May 13

Abstract Solid positions in the niche gastroenterology and cystic fibrosis treatment markets Relatively diverse product portfolio for company its size Competes against much larger rivals Adjusted debt...

May 2013

Drug Delivery Technologies - Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies

Overview The drug delivery industry has in recent years become a key partner for pharmaceutical companies in their efforts to maximize the patent lives of successful products Drug delivery companies...

September 2008
FROM

Pancreatitis Global Clinical Trials Review, Q1, 2011

Pancreatitis Global Clinical Trials Review, Q1, 2011 Summary Our clinical trial report, “Pancreatitis Global Clinical Trials Review, Q1, 2011" provides data on the Pancreatitis clinical trial scenario....

January 2011
FROM

Oral Drug Delivery Market - Controlled and Sustained Release to be Major Revenue Generators

“Oral Drug Delivery Market - Controlled and Sustained Release to be Major Revenue Generators”, provides the key data and analyzes the major challenges and drivers for the Oral Drug Delivery Market The...

November 2010
FROM
Chiesi Farmaceutici SpA - Product Pipeline Review - 2012 Chiesi Farmaceutici SpA - Product Pipeline Review - 2012 - Product Thumbnail Image

Chiesi Farmaceutici SpA - Product Pipeline Review - 2012

Chiesi Farmaceutici SpA – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “Chiesi Farmaceutici SpA - Product Pipeline Review - 2012” provides data on the Chiesi...

November 2012
FROM
Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013 Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013 - Product Thumbnail Image

Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013

Daewoong Pharmaceutical Co., Ltd. – Product Pipeline Review – 2013 Summary Global Market Direct’s pharmaceuticals report, “Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013” provides...

April 2013
FROM
Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012 Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012 - Product Thumbnail Image

Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012

Daewoong Pharmaceutical Co., Ltd. – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012” provides...

October 2012
FROM
Summary: Aptalis Pharma Inc. Nov 12 Summary: Aptalis Pharma Inc. Nov 12 - Product Thumbnail Image

Summary: Aptalis Pharma Inc. Nov 12

Abstract The ratings on New Jersey-based specialty pharmaceutical company Aptalis Pharma Inc. reflect what Standard & Poor's Ratings Services sees as the company's weak business risk profile, aggressive...

November 2012
Research Update: Aptalis Pharma Inc. Sr Secured Debt Rating Lowered To 'BB-' From 'BB' On Assessed Lower Enterprise Value; CCR Affirmed Jan 12 Research Update: Aptalis Pharma Inc. Sr Secured Debt Rating Lowered To 'BB-' From 'BB' On Assessed Lower Enterprise Value; CCR Affirmed Jan 12 - Product Thumbnail Image

Research Update: Aptalis Pharma Inc. Sr Secured Debt Rating Lowered To 'BB-' From 'BB' On Assessed Lower Enterprise Value; CCR Affirmed Jan 12

Abstract New Jersey-based specialty pharmaceutical company Aptalis Pharma Inc. continues to integrate Eurand N.V., which the company acquired in early 2011. As a result, Standard & Poor's is lowing...

January 2012
Aptalis Pharma Inc. Senior Secured Debt Rating Lowered To 'BB-' From 'BB' On Assessed Lower EV; CCR Affirmed Jan 12 Aptalis Pharma Inc. Senior Secured Debt Rating Lowered To 'BB-' From 'BB' On Assessed Lower EV; CCR Affirmed Jan 12 - Product Thumbnail Image

Aptalis Pharma Inc. Senior Secured Debt Rating Lowered To 'BB-' From 'BB' On Assessed Lower EV; CCR Affirmed Jan 12

Abstract New Jersey-based specialty pharmaceutical company Aptalis Pharma Inc. continues to integrate Eurand N.V., which the company acquired in early 2011. As a result, Standard & Poor's is lowing...

January 2012

Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2014

Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2014’, provides an overview of the Exocrine Pancreatic...

May 2014
FROM

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2013

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2013', provides an overview of the indication’s...

December 2013
FROM
Loading Indicator

Our Clients

NBC Universal Inc. Samsung Group Ltd. E.ON SE DHL International GmbH University of Cambridge Kone Oyj BP Plc.